Tscan Therapeutics Inc Financial Flexibility Index
Tscan Therapeutics Inc financial flexibility index. Tscan Therapeutics Inc (TCRX) has a Financial Flexibility Index of -0.26x as of June 2026. Free cash flow of $-27.04 Million (operating CF $-27.54 Million minus capex $493.00K) represents 0% of total liabilities ($102.43 Million). See Tscan Therapeutics Inc (TCRX) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Tscan Therapeutics Inc (2019–2025)
Financial flexibility index of Tscan Therapeutics Inc from 2019 to 2025. Historical Financial Flexibility Index trend for Tscan Therapeutics Inc across 7 annual periods. Explore Tscan Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Tscan Therapeutics Inc Financial Flexibility Index by Year (2019–2025)
Tscan Therapeutics Inc financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for Tscan Therapeutics Inc. For the full cash flow conversion analysis, see Tscan Therapeutics Inc (TCRX) cash conversion ratio.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -1.24x | $-130.91 Million | $-135.32 Million | $105.67 Million | ▼ -50.7% |
| 2024 | -0.82x | $-107.00 Million | $-110.82 Million | $130.15 Million | ▼ -71.3% |
| 2023 | -0.48x | $-58.21 Million | $-61.36 Million | $121.28 Million | ▲ +23.2% |
| 2022 | -0.62x | $-62.28 Million | $-66.50 Million | $99.66 Million | ▲ +55.9% |
| 2021 | -1.42x | $-38.74 Million | $-48.68 Million | $27.33 Million | ▼ -10855.9% |
| 2020 | 0.01x | $1.22 Million | $-3.02 Million | $92.20 Million | ▲ +100.8% |
| 2019 | -1.65x | $-11.28 Million | $-12.52 Million | $6.84 Million | — |